SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Social media platforms are seeing a surge in speculative chatter as investors debate the legitimacy of tokenized pre-IPO assets, with many users warning of potential scams while others track news regarding a long-rumored SpaceX public offering. Community members are actively analyzing the aerospace sector, focusing on the potential impact of a high-profile IPO and debating whether current market excitement reflects genuine valuation or a bubble driven by retail FOMO.

Goldman Sachs ETF Trust - Goldman Sachs Nasdaq-100 Premium Income ETF

Goldman Sachs ETF Trust - Goldman Sachs Nasdaq 100 Core Premium Income ETF

Investors are actively comparing GPIQ against established Nasdaq-100 income competitors like JEPQ and QQQI, with community debate centered on NAV stability, tax efficiency, and total return performance. The stock is trending as participants weigh its potential for growth and monthly cash flow against other derivative income strategies for long-term portfolio building.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining significant traction among investors who are actively discussing its potential to benefit from domestic supply chain reshoring and a strategic focus on metals-tech integration. The community sentiment is polarized between those viewing it as a resilient, long-term play in a volatile metals market and skeptics who are cautious about low-volume trading patterns, bot activity, and the inherent risks associated with its recent deSPAC transition.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to positive Phase III ReSPECT trial results for its antifungal drug REZZAYO, which met primary endpoints and signals potential expansion into a significant new market. Investors are actively debating the commercial timeline for this new indication, while monitoring the ongoing adoption of its primary product, DefenCath, within major dialysis organizations.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care is trending as investors monitor the company's progress with its DefenCath infection-prevention initiative, which the community highlights for its potential to improve patient outcomes and drive operating efficiency. Discussions are heavily focused on the company's role as a major player in the dialysis sector and how its operational strategies, including potential acquisitions and cost-saving measures, may influence its long-term market position.

Modine Manufacturing Co. engages in the provision of thermal management products and solutions. It operates through the Climate Solutions and Performance Technologies business segments. The Climate Solutions segment provides climate-controlled solutions and components, heat transfer products, heating, ventilating, air conditioning and refrigeration products, and data center cooling solutions. The Performance Technologies segment designs and manufactures air- and liquid-cooled technology for vehicular, stationary power, and industrial applications. In addition, the Performance Technologies segment provides thermal solutions to zero-emission and hybrid commercial vehicle and automotive customers, and coating products and application services. The company was founded by Arthur B. Modine on June 23, 1916 and is headquartered in Racine, WI.

Modine Manufacturing Co.

Modine Manufacturing is capturing intense investor attention as it positions itself as a pure-play leader in data center thermal management, a critical infrastructure bottleneck for the surging AI and hyperscale compute sector. The community is actively debating the company's valuation against its aggressive growth targets and upcoming spinoff, with many tracking it alongside industry peers as a key play on physical AI infrastructure.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending due to the completion of its $6.7 billion acquisition of Terns Pharmaceuticals, a move aimed at bolstering its oncology pipeline and securing new growth avenues ahead of the 2028 patent cliff for Keytruda. Investors are actively discussing the strategy of acquiring mid-stage clinical assets to maintain market dominance, while simultaneously monitoring other biotech entities as potential takeover targets to fill Merck's oncology gap.

Vishay Intertechnology, Inc. engages in the manufacture and distribution of discrete semiconductors and passive electronic components. It operates through the following segments: MOSFET (metal oxide semiconductor field-effect transistor), Diodes, Optoelectronic Components, Resistors, Inductors, and Capacitors. The MOSFET segment offers semiconductors which function as solid state switches to control power. The Diodes segment produces semiconductors which route, regulate, and block radio frequency, analog, and power signals, protect systems from surges or electrostatic discharge damage, and provide electromagnetic interference filtering. The Optoelectronic Components segment includes components that emit light, detect light, or do both. The Resistors and Inductors segment deals with components that impede electric current. The Capacitors segment provides components which store energy and discharge it when needed. The company was founded by Felix Zandman in 1962 and is headquartered in Malvern, PA.

Vishay Intertechnology, Inc.

Vishay Intertechnology is attracting significant investor interest as a foundational semiconductor recovery play, driven by robust call option activity and its strategic positioning in high-growth infrastructure sectors like smart home sensing and grid modernization. The community is actively discussing its potential for structural growth as the company transitions from low-volatility accumulation into a more active trend phase, buoyed by expanding volume and key component demand.

Tidal Trust II - Nicholas Crypto Income ETF

BLOX is currently attracting interest as investors navigate high-yield crypto income ETFs, with community members actively comparing its distribution performance against other similar funds like MSTY, BTCI, and MAGY. Many participants are focused on a "buy the dip" strategy and weekly dividend reinvestment, banking on long-term appreciation in the crypto market.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending as investors debate the impact of AI on enterprise SaaS, with community members weighing in on recent leadership changes and whether AI disruption fears are overblown given the company's resilient role in HR and finance workflows. The stock remains a focal point for institutional capital and trader sentiment as participants track whether its current valuation offers a recovery opportunity amid broader software sector volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomerica, Inc. Q2 Loss Widens

(RTTNews) - Biomerica, Inc. (BMRA) announced earnings for its second quarter that Increased from the same period last year...

Shares of Biomerica, Inc. (BMRA) traded nearly 26% lower on Wednesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biomerica.com/news/news-details/2025/Biomerica-Announces-Reverse-Stock-Split/default.aspx">said</a> it would implement a 1-for-8 reverse stock split of the issued and outstanding shares of its common stock to increase its bid price.The stock split will be effective at 12:01 a.m. ET on April 21, and Biomerica’s common stock will begin trading on a split-adjusted basis when the market opens on Monday, the company said.Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock, subsequently reducing the number of outstanding shares from about 20.4 million to about 2.5 million.The move is aimed at enabling the biomedical technology company to regain compliance with the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market.To regain compliance, Biomerica’s common stock must close at or above a $1.00 per share bid price for at least ten consecutive business days prior to May 5.On Stocktwits, retail sentiment around Biomerica fell from ‘extremely bullish’ to ‘bearish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’.<figure class="image"><img style="aspect-ratio:1306/306;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_1_33_21_PM_png_82a4f25b9a.webp" alt="BMRA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 16, 2025 | Source: Stocktwits" width="1306" height="306"><figcaption>BMRA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that today marks a good opportunity to buy the stock as the reverse split is “not that big of a deal” and the company has a strong cash runway.<stembedurl>https://stocktwits.com/ildamiano1/message/611809693</stembedurl>Biomerica’s cash and cash equivalents totaled $3.06 million as of February-end, marking an increase from $2.37 million at the end of the second quarter (Q2) of fiscal 2025.<a href="https://stocktwits.com/symbol/BMRA">BMRA stock</a> is up by about 42% year-to-date but has fallen 43% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ford-made-900-million-dollars-from-china-business-in-2024-report/chQPqv2RbOH">Ford Made $900M From China Business In 2024, Says Report: Retail Sentiment Brightens But Still Bearish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Biomerica Stock Slumps After Reverse Stock Split Announcement: Retail’s Disappointed

Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock on Monday.

Equity

Medical diagnostic product maker Biomerica Inc. emerged as the top biotech stock with the highest jump in new retail followers on Stocktwits Friday.Shares of the nanocap company tumbled over 9% on Friday afternoon, following a 100% surge in the prior session — its best single-day performance since March 18, 2020, when the stock more than quadrupled.On Thursday, Biomerica announced that its Fortel Prostate Specific Antigen (PSA) Screening Test received approval from the UAE Ministry of Health and Prevention.&nbsp;The test offers rapid and accurate results in just 10 minutes using a simple finger-prick blood sample, measuring PSA levels, an established early marker of prostate disease.The accessible nature of the test is designed to facilitate early detection of prostate cancer and related conditions, aiming to improve patient outcomes, reduce strain on healthcare systems, and encourage proactive health management, the company said.The UAE approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.&nbsp;The company previously achieved regional success with its EZ Detect Colon Disease At-Home Screening Test, which secured government insurance reimbursement in Dubai.Biomerica said it is working to replicate this success with the Fortel PSA test, establishing partnerships with key distributors and securing regulatory approvals to improve accessibility to early cancer detection solutions.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BMRA_sentiment_and_message_volume_Jan_17_cec1cb6947.png" alt="BMRA sentiment and message volume Jan 17.png" width="1318" height="324"><figcaption>BMRA sentiment and message volume Jan 17 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Despite Friday’s stock dip, likely driven by profit-taking, retail sentiment on Stocktwits remained ‘bullish’, with a notable rise in message volume.&nbsp;Many retail investors indicated they were “buying the dip,” as chatter about the stock soared.<stembedurl>https://stocktwits.com/chaudaaary/message/600490675</stembedurl><stembedurl>https://stocktwits.com/Gunsmoke16/message/600488437</stembedurl><stembedurl>https://stocktwits.com/543688Ireland/message/600474360</stembedurl>Biomerica’s retail follower count on Stocktwits has climbed nearly 5% over the past year, while message volume has soared over a thousand-fold, even as the stock has shed more than 31% in value during the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prostate cancer cells, 3D illustration. Prostate cancer awareness image. | Image source: KATERYNA KON/SCIENCE PHOTO LIBRARY via Getty Images

Biomerica Adds Most New Retail Followers Among Biotechs After UAE Nod For Prostate Cancer Screening Test

The latest approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

Current Price	$2.34
Prev Close	$2.41
Open	$2.42
Dividend Yield	0.00%
50-Day Moving Average	$2.15
Beta	1.17
Avg. Volume	22,833.31
PE Ratio	-1.56

52-Week High	$4.60
52-Week Low	$1.87
Market Capitalization	$7.23M
EPS (Annual)	-$2.16
Price to Book	2.14
Revenue Per Employee	$98,351.85

BMRA
Biomerica Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest BMRA News

BMRABiomerica Inc.